<div class="container">

<table style="width: 100%;"><tr>
<td>power.tsd.KM</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Power calculation of adaptive 2-stage BE studies (2x2 crossover)
(variant of power.2stage to obtain the results of Karalis / Macheras)
</h2>

<h3>Description</h3>

<p>This function calculates the ‘empiric’ power of 2-stage BE studies according
to Potvin <em>et al.</em> via simulations. The Potvin methods are modified as
described by Karalis &amp; Macheras to include a futility criterion Nmax and to
perform the power calculation steps and the sample size estimation step in
the decision schemes with the <abbr><span class="acronym">MSE</span></abbr> (calculated from CV) <strong>and</strong>
the point estimate (<abbr><span class="acronym">PE</span></abbr>) of T/R from stage 1.
</p>


<h3>Usage</h3>

<pre><code class="language-R">power.tsd.KM(method = c("C", "B"), alpha0 = 0.05, alpha = c(0.0294, 0.0294),
             n1, CV, targetpower = 0.8, pmethod = c("nct", "exact"),
             Nmax = 150, theta0, theta1, theta2, npct = c(0.05, 0.5, 0.95),
             nsims, setseed = TRUE, details = FALSE)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>method</code></td>
<td>

<p>Decision schemes according to Potvin <em>et al.</em><br>
Default is <code style="white-space: pre;">⁠"C"⁠</code> aka <abbr><span class="acronym">TSD</span></abbr> in the paper of Karalis &amp; Macheras
if setting <code style="white-space: pre;">⁠alpha=c(0.0294, 0.0294)⁠</code>.<br><abbr><span class="acronym">TSD-1</span></abbr> of Karalis can be obtained by choosing <code style="white-space: pre;">⁠"C"⁠</code> but
setting <code style="white-space: pre;">⁠alpha=c(0.028, 0.028)⁠</code>.<br><abbr><span class="acronym">TSD-2</span></abbr> of Karalis can be obtained by choosing <code style="white-space: pre;">⁠"B"⁠</code> and
setting <code style="white-space: pre;">⁠alpha=c(0.0294, 0.0294)⁠</code>.<br></p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>alpha0</code></td>
<td>

<p>Alpha value for the first step(s) in Potvin C aka <abbr><span class="acronym">TSD</span></abbr> of Karalis &amp;
Macheras or <abbr><span class="acronym">TSD-1</span></abbr> of Karalis, the power inspection and BE decision
if power &gt; targetpower.<br>
Defaults to 0.05.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>

<p>Vector (two elements) of the nominal alphas for the two stages.<br>
Defaults to Pocock’s alpha setting <code style="white-space: pre;">⁠alpha=c(0.0294, 0.0294)⁠</code>
as in <abbr><span class="acronym">TSD</span></abbr> of Karalis &amp; Macheras.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n1</code></td>
<td>

<p>Sample size of stage 1.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CV</code></td>
<td>

<p>Coefficient of variation of the intra-subject variability
(use <em>e.g.</em>, 0.3 for 30%).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>targetpower</code></td>
<td>

<p>Power threshold in the first step of Potvin <code style="white-space: pre;">⁠"C"⁠</code> and power to
achieve in the sample size estimation step.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>pmethod</code></td>
<td>

<p>Power calculation method, also to be used in the sample size estimation for
stage 2.<br>
Implemented are "<code style="white-space: pre;">⁠"nct"⁠</code> (approximate calculations via non-central
<em>t</em>-distribution and <code style="white-space: pre;">⁠"exact"⁠</code> (exact calculations via Owen’s Q).<br>
Defaults to <code style="white-space: pre;">⁠"nct"⁠</code> as a reasonable compromise between speed and
accuracy in the sample size estimation step.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>Nmax</code></td>
<td>

<p>Futility criterion. If set to a finite value all studies simulated in which
a sample size &gt;Nmax is obtained will be regarded as BE=FAIL. Defaults to 150,
as recommended by Karalis &amp; Macheras.<br>
Set this argument to <code style="white-space: pre;">⁠Inf⁠</code>, to work without that futility criterion.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta0</code></td>
<td>

<p>Assumed ratio of geometric means (T/R) for simulations. If missing,
defaults to <code style="white-space: pre;">⁠GMR⁠</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta1</code></td>
<td>

<p>Lower bioequivalence limit. Defaults to 0.8.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta2</code></td>
<td>

<p>Upper bioequivalence limit. Defaults to 1.25.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>npct</code></td>
<td>

<p>Percentiles to be used for the presentation of the distribution of
<code style="white-space: pre;">⁠n(total)=n1+n2⁠</code>.<br>
Defaults to <code style="white-space: pre;">⁠c(0.05, 0.5, 0.95)⁠</code> to obtain the 5% and 95% percentiles
and the median.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nsims</code></td>
<td>

<p>Number of studies to simulate.<br>
If missing, <code style="white-space: pre;">⁠nsims⁠</code> is set to 1E+05 = 100,000 or to 1E+06 = 1 Mio
if estimating the empiric Type I Error (<code style="white-space: pre;">⁠'alpha'⁠</code>), <em>i.e.</em>,
with <code style="white-space: pre;">⁠theta0⁠</code> at the border or outside the acceptance range
<code style="white-space: pre;">⁠theta1⁠</code> ... <code style="white-space: pre;">⁠theta2⁠</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>setseed</code></td>
<td>

<p>Simulations are dependent on the starting point of the (pseudo) random number
generator. To avoid differences in power for different runs a
<code>set.seed(1234567)</code> is issued if <code style="white-space: pre;">⁠setseed=TRUE⁠</code>, the default.<br>
Set this argument to <code style="white-space: pre;">⁠FALSE⁠</code> to view the variation in power between
different runs.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>details</code></td>
<td>

<p>If set to <code style="white-space: pre;">⁠TRUE⁠</code> the function prints the results of time measurements
of the simulation steps. Defaults to <code style="white-space: pre;">⁠FALSE⁠</code>.
</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>The calculations follow in principle the simulations as described in Potvin
<em>et al</em>.<br>
The underlying subject data are assumed to be evaluated after log-transformation.
But instead of simulating subject data, the statistics pe1, mse1 and pe2, SS2 are
simulated via their associated distributions (normal and
χ<sup>2</sup> distributions).<br><br>
In contrast to Potvin <em>et al.</em> the power calculation steps as well as the
sample size adaption step of the decision schemes are done using the <abbr><span class="acronym">MSE</span></abbr>
(calculated from CV) <b>and</b> the point estimate from
stage 1.<br>
This resembles the methods described in Karalis &amp; Macheras and Karalis.
</p>


<h3>Value</h3>

<p>Returns an object of class <code style="white-space: pre;">⁠"pwrtsd"⁠</code> with all the input arguments and results
as components.<br>
The class <code style="white-space: pre;">⁠"pwrtsd"⁠</code> has a S3 print method.<br>
The results are in the components:
</p>
<table>
<tr style="vertical-align: top;">
<td><code>pBE</code></td>
<td>
<p>Fraction of studies found BE.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>pBE_s1</code></td>
<td>
<p>Fraction of studies found BE in stage 1.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>pct_s2</code></td>
<td>
<p>Percentage of studies continuing to stage 2.</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nmean</code></td>
<td>
<p>Mean of n(total).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nrange</code></td>
<td>
<p>Range (min, max) of n(total).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nperc</code></td>
<td>
<p>Percentiles of the distribution of n(total).</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>ntable</code></td>
<td>
<p>Object of class <code style="white-space: pre;">⁠"table"⁠</code> summarizing the discrete distribution
of n(total) via its distinct values and counts of occurences of these values.<br>
This component is only given back if <code style="white-space: pre;">⁠is.finite(Nmax)⁠</code>.</p>
</td>
</tr>
</table>
<h3>Author(s)</h3>

<p>D. Labes
</p>


<h3>References</h3>

<p>Potvin D, DiLiberti CE, Hauck WW, Parr AF, Schuirmann DJ, Smith RA. <em>Sequential design approaches for bioequivalence studies with crossover designs.</em><br>
Pharm Stat. 2008; 7(4):245–62. doi: <a href="https://doi.org/10.1002/pst.294">10.1002/pst.294</a>
</p>
<p>Karalis V, Macheras P. <em>An Insight into the Properties of a Two-Stage Design in Bioequivalence Studies.</em><br>
Pharm Res. 2013; 30(7):1824–35. doi: <a href="https://doi.org/10.1007/s11095-013-1026-3">10.1007/s11095-013-1026-3</a>
</p>
<p>Karalis V. <em>The role of the upper sample size limit in two-stage bioequivalence designs.</em><br>
Int J Pharm. 2013; 456(1):87–94. doi: <a href="https://doi.org/10.1016/j.ijpharm.2013.08.013">10.1016/j.ijpharm.2013.08.013</a>
</p>
<p>Fuglsang A. <em>Futility Rules in Bioequivalence Trials with Sequential Designs.</em><br>
AAPS J. 2014; 16(1):79–82. doi: <a href="https://doi.org/10.1208/s12248-013-9540-0">10.1208/s12248-013-9540-0</a>
</p>
<p>Schütz H. <em>Two-stage designs in bioequivalence trials.</em><br>
Eur J Clin Pharmacol. 2015; 71(3):271–81. doi: <a href="https://doi.org/10.1007/s00228-015-1806-2">10.1007/s00228-015-1806-2</a>
</p>


<h3>Examples</h3>

<pre><code class="language-R"># using all the defaults
# but too low number of sims to complain with the CRAN policy:
# "check time only a few seconds per example"
# minimum number of sims should be 1E5 for power, 1E6 sims for 'alpha'
power.tsd.KM(n1=16, CV=0.2, nsims=1E4)
# ~3 sec if nsims=1E5
</code></pre>


</div>